Philips announced the commercial launch of its next‑generation Bridge Plus Occlusion Balloon, a device engineered to rapidly control bleeding from superior vena cava (SVC) tears that can occur during transvenous lead extraction procedures. The balloon can deploy in less than two minutes—averaging 58.33 seconds in testing—stop up to 90% of blood loss, and maintain hemostasis for at least 30 minutes, giving electrophysiology teams critical time to stabilize patients and arrange surgical repair.
SVC tears are a rare but high‑mortality complication, occurring in fewer than 0.5% of lead‑extraction cases. Studies show that the availability of an occlusion balloon improves survival rates from 56.9% to 88.2%, underscoring the life‑saving potential of the Bridge Plus. The device is now available in the United States and will be showcased at the Heart Rhythm Society conference in Chicago on April 24‑26, 2026.
The Bridge Plus builds on Philips’ existing Bridge Occlusion Balloon technology, which has been used in more than 50,000 U.S. procedures. The new model received FDA 510(k) clearance (K251358) with an expiration date of July 31, 2026, and international availability is expected later in 2026. "Ensuring procedural safety is a top priority for electrophysiology teams. Bridge Plus builds on established technology to help physicians prepare for rare SVC tears and respond quickly with the control needed to stabilize patients and transition to surgery," said Stacy Beske, Business Leader, Image‑Guided Therapy Devices at Philips.
The launch expands Philips’ portfolio of lead‑management solutions and positions the company to address a high‑stakes complication that can jeopardize patient safety. By providing a rapid, effective response to SVC tears, Philips strengthens its presence in the electrophysiology market and reinforces its commitment to patient‑centric innovation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.